

Rowan University

Rowan Digital Works

Stratford Campus Research Day

26th Annual Research Day

May 5th, 12:00 AM

Bullous Pemphigoid with Excoriation Disorder in a 59 Year Old Woman

Kaitlin McGowan
Rowan University

Stephen Poos
Rowan University

Nguyen Vo
Ocean University Medical Center - Hackensack Meridian Health

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day



Part of the [Dermatology Commons](#), [Pathological Conditions, Signs and Symptoms Commons](#), [Psychiatric and Mental Health Commons](#), [Psychiatry Commons](#), and the [Skin and Connective Tissue Diseases Commons](#)

Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

McGowan, Kaitlin; Poos, Stephen; and Vo, Nguyen, "Bullous Pemphigoid with Excoriation Disorder in a 59 Year Old Woman" (2022). *Stratford Campus Research Day*. 20.
https://rdw.rowan.edu/stratford_research_day/2022/May5/20

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of Rowan Digital Works.

Bullous Pemphigoid with Excoriation Disorder in a 59-Year-Old Woman

Kaitlin McGowan, Stephen Poos, & Nguyen Vo, MD

Rowan University School of Osteopathic Medicine, Stratford, NJ 08084

Hackensack Meridian Ocean University Medical Center, Brick, NJ 087

Background

- Bullous pemphigoid is the most common autoimmune blistering disease.
- Classic symptoms include blisters overlying urticarial plaques on the torso and extremities.
- Etiology includes an abnormal T-cell response that triggers production of IgG and IgE autoantibodies which attack the hemidesmosomes of the basement membrane (1).
- The condition can result in intense pruritus that begins during the prodromal period (2).
- Excoriation disorder is related to obsessive-compulsive disorder (OCD) and is characterized by recurrent skin picking that results in lesions, repeated attempts to stop or decrease the picking, and resultant mental distress or impairment in functioning (3,4).

Patient Presentation

- 59-year-old Caucasian female presented with diffuse rash of all four extremities, trunk, abdomen, and back but sparing the upper feet and face. The current rash had been present for the past four months but the patient had a recurring rash “on and off for the past year”.
- Unable to associate symptoms with change in medication or illness.
- Rash associated with diffuse itching and burning pain.
- Uncontrollable urge to pick at skin in response to feelings of anxiety.
- Denied fever, chills, weakness, or recent insect bites.
- Medical History: type 2 diabetes, polycystic ovarian syndrome, eczema, and bipolar disorder type II, anxiety, depression
- Family History: no history of autoimmune disease
- Medications: duloxetine 60 mg daily (started 1 month ago), triamcinolone 0.5% cream BID as needed for eczema, atorvastatin 40 mg, metformin 500 mg, hydroxyzine HCl 25 mg BID, metoprolol succinate 25 mg, oxybutynin 15 mg, aspirin 81 mg




Figure A: Diffuse rash of posterior torso

Figure B: A 2 cm closed bullous lesion containing clear serosanguinous fluid seen on the right medial lower extremity

Figure C: Diffuse scabs on the anterior neck region

- Physical Exam:
 - Severe rash of the lower face, neck, chest, trunk, and extremities with an erythematous base accompanied by moderate diffuse excoriation and severe dryness (Figures A-C).
 - No lesions of mucosa of the oropharynx or nares.
 - Clear bullae filled with serosanguinous fluid and scabs in stages of healing (Figure B).
 - Bullae did not slough off when pressure was applied.

Investigation

- Two punch biopsies were taken, one from each thigh.
- Histology showed subepidermal bullous dermatosis with mixed inflammatory infiltrate of predominantly eosinophils (Figures D and E).
- Direct immunofluorescence of samples demonstrated linear deposition of IgG and C3 along the basement membrane (Figure F).
- Leukemia panel of the peripheral blood indicated no diagnostic immunophenotypic abnormalities detected by flow cytometry.
- Findings consistent with bullous pemphigoid.




Figure D: Subepidermal bullous dermatosis with mixed inflammatory infiltrate in the blister cavity (10x magnification).

Figure E: The mixed inflammatory infiltrate in the subepidermal blister cavity consists predominantly of eosinophils (40x magnification).

Figure F: Direct immunofluorescence shows linear deposition of IgG (primarily IgG4) and C3 along the basement membrane.

Treatment and Outcome

- Single dose of methylprednisolone 125 mg IV given in emergency room
- Four day course of IV vancomycin 15 mg/kg Q12 hours
- Cross tapered from duloxetine to fluoxetine 40 mg daily to treat excoriation disorder
- Discharged on oral prednisone taper starting at 60 mg and decreasing by 10 mg every five days until complete
- Referred for outpatient psychotherapy
- Significant improvement in skin symptoms on prednisone taper before lost to follow up 3 months later

Discussion

- Treatment for bullous pemphigoid with Level 1A evidence typically includes systemic steroids for severe cases and topical clobetasol for mild to moderate cases (1).
- Treatment for excoriation disorder involves psychotherapy, such as cognitive behavior therapy or habit reversal therapy. Pharmacotherapy options include SSRIs and lamotrigine (5).
- Excoriation disorder is related to OCD, for which fluoxetine is known to be especially efficacious (6).
- There is emerging yet still controversial evidence suggesting links between bullous pemphigoid and neuropsychiatric conditions. Some studies have found increased incidence of bullous pemphigoid in patients with psychiatric histories including those with major depressive disorder and bipolar depression (7,8).
- Diagnosis was made with direct immunofluorescence that showed linear deposition of IgG and C3 along the basement membrane (Figure F).
- Alternative diagnostic methods include:
 - Serological detection of autoantibodies by indirect immunofluorescence on human salt-split skin (9)
 - ELISA using recombinant fragments of BP180 and BP230 (9)
- This particular case is notable for its concurrent severe dermatological and psychiatric components.

Acknowledgements

- We would like to thank the pathology department at Ocean University Medical Center for their support and assistance. We would also like to acknowledge Harvard Vanguard Medical Associates for their expert dermatopathology consultation.

References

1. Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. *An Bras Dermatol.* 2019;94(2):133-46.
2. Alonso-Llamazares J, Rogers RS, 3rd, Oursler JR, Calobrisi SD. Bullous pemphigoid presenting as generalized pruritus: observations in six patients. *Int J Dermatol.* 1998;37(7):508-14.
3. Grant JE, Chamberlain SR. Prevalence of skin picking (excoriation) disorder. *J Psychiatr Res.* 2020;130:57-60.
4. American Psychiatric Association. Excoriation (skin-picking) disorder. In: *The diagnostic and statistical manual of mental disorders.* 5th ed. Washington DC: American Psychiatric Publishing; 2013. p. 254-257.
5. Lochner C, Roos A, Stein DJ. Excoriation (skin-picking) disorder: a systematic review of treatment options. *Neuropsychiatr Dis Treat.* 2017;13:1867-72.
6. Skapinakis P, Caldwell D, Hollingworth W, Bryden P, Fineberg N, Salkovskis P, et al. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. *Health Technol Assess.* 2016;20(43):1-392.
7. Försti AK, Jokelainen J, Ansakorpi H, Seppänen A, Majamaa K, Timonen M, et al. Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide Finnish Care Register study. *Sci Rep.* 2016;6:37125.
8. Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. *J Invest Dermatol.* 2011;131(3):637-43.
9. Schulze F, Kasperkiewicz M, Zillikens D, Schmidt E. [Bullous pemphigoid]. *Hautarzt.* 2013;64(12):931-43; quiz 44-5.